Dermal Papilla Cell Platform
Targeting Hair Regeneration at the Cellular Root
Dermal papilla cells sit at the base of the hair follicle and help regulate the hair growth cycle. HanBio’s DPC platform is designed to isolate, expand, and apply these cells through proprietary technologies focused on hair follicle regeneration research and clinical translation.
Traditional DPC research has faced three major barriers:
- Small tissue size — DPCs are difficult to isolate exclusively from scalp tissue.
- Low initial cell yield — isolated cells are limited in number and may vary by donor and culture condition.
- Functional decline during expansion — DPCs can lose hair-inductive properties over successive passages
Chopping Isolation Technology
A proprietary method for isolating dermal papilla cells from scalp tissue.
Mass Culture Optimization
Culture optimization intended to support scalable DPC expansion.
Cell Permeation / Transplantation Technology
A proprietary approach related to applying cultured DPCs into the scalp environment.
Hair Growth Factor Development
DPC-derived growth factor research supporting next-generation hair and scalp products.
HXF-101 is HanBio’s lead autologous dermal papilla cell therapy candidate for androgenetic alopecia. The program involves follicle harvesting, DPC isolation, cell expansion, 3D papilla-like aggregate formation, product preparation, and administration planning.
HXF-101 is a development-stage therapeutic candidate and is subject to regulatory review. Availability, indications, and claims may vary by jurisdiction.
This sentence is important. For a global site, safe language is not boring — it keeps the lawyers from kicking down the door wearing lab coats.
